DDDR-22. Fingolimod targets Cushing’s disease adenomas in-vitro and in-vivo
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0659
Abstract: Cushing’s disease (CD) causes severe morbidity and up to 50% higher mortality despite best medical practices. Effective targeted therapies are lacking for CD. Our objective was to identify and test novel agents targeting CD. We… read more here.
Keywords: cushing disease; fingolimod targets; dddr fingolimod; vitro vivo ... See more keywords
Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells
Sign Up to like & getrecommendations! Published in 2019 at "PeerJ"
DOI: 10.7717/peerj.7733
Abstract: Background Synthetic cannabinoids are a commonly used class of recreational drugs that can have significant adverse effects. There have been sporadic reports of co-consumption of illicit drugs with rodenticides such as warfarin and brodifacoum (BFC)… read more here.
Keywords: att20 cells; cannabinoid; cb2; bfc ... See more keywords